The Novo, Pfizer and Nan Fung-backed oncology therapy developer priced an upsized offering above its range and is now valued above $1bn.
Bolt Biotherapeutics, a US-based cancer drug developer that counts pharmaceutical firms Pfizer and Novo and real estate developer Nan Fung as investors, went public on Friday raising $230m.
The company issued 11.5 million shares priced at $20 each in the initial public offering, increased from 8.8 million, while the share price was above the IPO’s $16 to $18 range. Its shares surged more than 60% to close at $32.15 on its first day of trading, giving it a market…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
